Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

Antimicrobial agents and chemotherapy - 1 Apr 2004

Ricci Vito, Peterson Marnie L, Rotschafer John C, Wexler Hannah, Piddock Laura J V

Abstract excerpt

Twelve laboratory mutants and 32 ciprofloxacin-resistant isolates of Bacteroides fragilis were examined for the mechanism(s) of fluoroquinolone resistance. Five mutants had mutations in gyrA. One mutant and two clinical isolates contained a mutation in gyrB. Eight mutants and five clinical isolat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Bacteroides fragilis
Share to DNA Gyrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Topoisomerase IV

Share to DNA Topoisomerases, Type I

Share to Drug Resistance, Bacterial

Share to Fluoroquinolones

Share to Microbial Sensitivity Tests

Source

Open in PubMed Open full text

Identifiers

PMID: 15047539
DOI: 10.1128/AAC.48.4.1344-1346.2004
PMCID: PMC375253

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-15047539-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.PMID 15047539Read ↗

Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin.Semantic proximity Read ↗

gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.Semantic proximity Read ↗

Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutantsSemantic proximity Read ↗

Genetic analysis of mechanisms of multidrug resistance in a clinical isolate of Bacteroides fragilisSemantic proximity Read ↗

Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.Semantic proximity Read ↗

Plasmid-mediated complementation of gyrA and gyrB in fluoroquinolone-resistant Bacteroides fragilis.Semantic proximity Read ↗

Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.Semantic proximity Read ↗

Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.Semantic proximity Read ↗

Contribution of enhanced efflux to reduced susceptibility of Salmonella enterica serovar Choleraesuis to fluoroquinolone and other antimicrobials.Semantic proximity Read ↗

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.Semantic proximity Read ↗

In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains.Semantic proximity Read ↗

Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.